Moxetumomab pasudotox-5mg

Description

Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL)[1][2][3].–Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Kreitman RJ, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35. |[2]hillon S. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78(16):1763-1767. |[3]Kinjyo I, et al. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26604. |[4]Müller F, et al. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875. |[5]Ksenia Matlawska-Wasowska, et al. Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking. Blood (2013) 122 (21): 5022. -CASNumber-1020748-57-5-MolecularWeight-63500 (average)-Compound Purity–SMILES-[Moxetumomab pasudotox]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);CD22-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Immunology/Inflammation-MCE Product type-ADC Related